Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Camrelizumab + Temozolomide in Advanced Melanoma
NCT05983237Phase 2Recruiting
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in melanoma. Started Aug 2023; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05983237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983237.